Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1958 1
1961 5
1962 3
1963 1
1965 3
1966 5
1967 3
1968 12
1969 8
1970 7
1971 11
1972 7
1973 7
1974 9
1975 5
1976 14
1977 9
1978 9
1979 22
1980 16
1981 14
1982 25
1983 24
1984 27
1985 35
1986 25
1987 37
1988 35
1989 41
1990 41
1991 38
1992 64
1993 65
1994 56
1995 55
1996 61
1997 46
1998 56
1999 55
2000 81
2001 74
2002 64
2003 81
2004 74
2005 64
2006 96
2007 96
2008 119
2009 125
2010 101
2011 125
2012 147
2013 131
2014 103
2015 110
2016 143
2017 134
2018 155
2019 188
2020 218
2021 214
2022 213
2023 179
2024 160

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,774 results

Results by year

Filters applied: . Clear all
Page 1
Macrophages transfer mitochondria to sensory neurons to resolve inflammatory pain.
van der Vlist M, Raoof R, Willemen HLDM, Prado J, Versteeg S, Martin Gil C, Vos M, Lokhorst RE, Pasterkamp RJ, Kojima T, Karasuyama H, Khoury-Hanold W, Meyaard L, Eijkelkamp N. van der Vlist M, et al. Among authors: kojima t. Neuron. 2022 Feb 16;110(4):613-626.e9. doi: 10.1016/j.neuron.2021.11.020. Epub 2021 Dec 17. Neuron. 2022. PMID: 34921782 Free article.
Validation of a New Methodology to Create Oral Drugs beyond the Rule of 5 for Intracellular Tough Targets.
Ohta A, Tanada M, Shinohara S, Morita Y, Nakano K, Yamagishi Y, Takano R, Kariyuki S, Iida T, Matsuo A, Ozeki K, Emura T, Sakurai Y, Takano K, Higashida A, Kojima M, Muraoka T, Takeyama R, Kato T, Kimura K, Ogawa K, Ohara K, Tanaka S, Kikuchi Y, Hisada N, Hayashi R, Nishimura Y, Nomura K, Tachibana T, Irie M, Kawada H, Torizawa T, Murao N, Kotake T, Tanaka M, Ishikawa S, Miyake T, Tamiya M, Arai M, Chiyoda A, Akai S, Sase H, Kuramoto S, Ito T, Shiraishi T, Kojima T, Iikura H. Ohta A, et al. Among authors: kojima t. J Am Chem Soc. 2023 Nov 8;145(44):24035-24051. doi: 10.1021/jacs.3c07145. Epub 2023 Oct 24. J Am Chem Soc. 2023. PMID: 37874670
First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50).
Kato K, Doki Y, Ogata T, Motoyama S, Kawakami H, Ueno M, Kojima T, Shirakawa Y, Okada M, Ishihara R, Kubota Y, Amaya-Chanaga C, Chen T, Matsumura Y, Kitagawa Y. Kato K, et al. Among authors: kojima t. Esophagus. 2023 Apr;20(2):291-301. doi: 10.1007/s10388-022-00970-1. Epub 2022 Nov 19. Esophagus. 2023. PMID: 36401133 Free PMC article. Clinical Trial.
Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 2.
Kitagawa Y, Ishihara R, Ishikawa H, Ito Y, Oyama T, Oyama T, Kato K, Kato H, Kawakubo H, Kawachi H, Kuribayashi S, Kono K, Kojima T, Takeuchi H, Tsushima T, Toh Y, Nemoto K, Booka E, Makino T, Matsuda S, Matsubara H, Mano M, Minashi K, Miyazaki T, Muto M, Yamaji T, Yamatsuji T, Yoshida M. Kitagawa Y, et al. Among authors: kojima t. Esophagus. 2023 Jul;20(3):373-389. doi: 10.1007/s10388-023-00994-1. Epub 2023 Mar 30. Esophagus. 2023. PMID: 36995449 Free PMC article. No abstract available.
Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).
Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M, Yoshii T, Kotani D, Tamura H, Mikamoto Y, Hirano N, Wakabayashi M, Nomura S, Sato A, Kuwata T, Togashi Y, Nishikawa H, Shitara K. Fukuoka S, et al. Among authors: kojima t. J Clin Oncol. 2020 Jun 20;38(18):2053-2061. doi: 10.1200/JCO.19.03296. Epub 2020 Apr 28. J Clin Oncol. 2020. PMID: 32343640 Clinical Trial.
A Single-Arm Confirmatory Study of Definitive Chemoradiation Therapy Including Salvage Treatment for Clinical Stage II/III Esophageal Squamous Cell Carcinoma (JCOG0909 Study).
Takeuchi H, Ito Y, Machida R, Kato K, Onozawa M, Minashi K, Yano T, Nakamura K, Tsushima T, Hara H, Okuno T, Hironaka S, Nozaki I, Ura T, Chin K, Kojima T, Seki S, Sakanaka K, Fukuda H, Kitagawa Y; Japan Esophageal Oncology Group of the Japan Clinical Oncology Group. Takeuchi H, et al. Among authors: kojima t. Int J Radiat Oncol Biol Phys. 2022 Nov 1;114(3):454-462. doi: 10.1016/j.ijrobp.2022.07.007. Epub 2022 Aug 4. Int J Radiat Oncol Biol Phys. 2022. PMID: 35932949
ACLP Activates Cancer-Associated Fibroblasts and Inhibits CD8+ T-Cell Infiltration in Oral Squamous Cell Carcinoma.
Sekiguchi S, Yorozu A, Okazaki F, Niinuma T, Takasawa A, Yamamoto E, Kitajima H, Kubo T, Hatanaka Y, Nishiyama K, Ogi K, Dehari H, Kondo A, Kurose M, Obata K, Kakiuchi A, Kai M, Hirohashi Y, Torigoe T, Kojima T, Osanai M, Takano K, Miyazaki A, Suzuki H. Sekiguchi S, et al. Among authors: kojima t. Cancers (Basel). 2023 Aug 28;15(17):4303. doi: 10.3390/cancers15174303. Cancers (Basel). 2023. PMID: 37686580 Free PMC article.
Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial.
Kato K, Machida R, Ito Y, Daiko H, Ozawa S, Ogata T, Hara H, Kojima T, Abe T, Bamba T, Watanabe M, Kawakubo H, Shibuya Y, Tsubosa Y, Takegawa N, Kajiwara T, Baba H, Ueno M, Takeuchi H, Nakamura K, Kitagawa Y; JCOG1109 investigators. Kato K, et al. Among authors: kojima t. Lancet. 2024 Jul 6;404(10447):55-66. doi: 10.1016/S0140-6736(24)00745-1. Epub 2024 Jun 11. Lancet. 2024. PMID: 38876133 Clinical Trial.
Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab.
Maeda Y, Wada H, Sugiyama D, Saito T, Irie T, Itahashi K, Minoura K, Suzuki S, Kojima T, Kakimi K, Nakajima J, Funakoshi T, Iida S, Oka M, Shimamura T, Doi T, Doki Y, Nakayama E, Ueda R, Nishikawa H. Maeda Y, et al. Among authors: kojima t. Nat Commun. 2021 Dec 14;12(1):7280. doi: 10.1038/s41467-021-27574-0. Nat Commun. 2021. PMID: 34907192 Free PMC article. Clinical Trial.
3,774 results